JNJ

Business profile & competitive position

Johnson & Johnson operates in the Healthcare sector, classified under Drug Manufacturers - General. In practice, it is a holding company whose subsidiaries employ roughly 138,200 people worldwide and develop, manufacture, and sell a broad range of healthcare products. The business is organized into two segments: Innovative Medicine, which brings in prescription therapeutics in Oncology, Immunology, Neuroscience, Pulmonary Hypertension, Infectious Diseases, and Cardiovascular and Metabolism; and MedTech, which makes products used in cardiovascular, orthopaedic, surgical, and vision procedures. These products reach retailers, wholesalers, distributors, hospitals, eye-care professionals, and healthcare providers across virtually all countries.

The company’s financial footprint points to a business with established pricing power and disciplined capital use. The latest data show a 21.5% net margin and a 25.7% return on equity — both well above what commodity-type businesses typically generate and consistent with an entrenched, branded healthcare franchise. That said, revenue concentration is worth noting: DARZALEX/DARZALEX FASPRO accounted for about 15.0% of 2025 total revenue, STELARA about 6.5%, and TREMFYA about 5.5%. Combined, those three products represented roughly 27% of revenue, which underlines the importance of blockbuster franchises and, by extension, patent and biosimilar risk. The stock’s beta of 0.23 also suggests very low sensitivity to broader market swings, fitting the defensive profile usually associated with large-cap pharma and medtech names.

Financial posture

With a market capitalization of $610.8 billion and a trailing price-to-earnings ratio of 29.3, Johnson & Johnson is priced as a premium large-cap healthcare operator rather than a deep-value name. The 21.5% net margin supports that valuation multiple by showing that a meaningful share of each revenue dollar reaches the bottom line, while the 25.7% ROE indicates effective use of shareholder equity. The 0.23 beta reinforces the low-volatility narrative: the stock historically moves far less than the overall market, a pattern often linked to durable cash flows and recession-resistant demand.

At the current snapshot, JNJ is trading at $253.44, below its 50-day exponential moving average of $263.58, with an RSI of 29.7. That technical position is typically interpreted as short-term oversold territory, but it is not itself a recommendation — only a context point for anyone analyzing recent price action.

Strategic priorities & outlook

The company’s most recent 10-K outlines a clear operational agenda. A headline priority is completing the planned separation of the Orthopaedics business, announced in October 2025, with a target completion window of 18 to 24 months from that announcement. That timeline implies a transaction likely aimed at simplifying the portfolio and sharpening the focus of the remaining Innovative Medicine and MedTech operations.

Beyond portfolio restructuring, the 10-K emphasizes human capital management built on three pillars: attracting and recruiting top talent, developing and retaining top talent, and empowering and inspiring talent. Operational culture is framed around a Credo-based environment focused on innovation, health, well-being, safety, inclusion, and belonging. The company also points to learning initiatives such as J&J Learn and the annual Global Learning Day as tools for building the talent pipeline tied to long-term strategy.

On the commercial side, the filing specifically flags that continued global launches of biosimilar versions of STELARA are expected to keep hurting STELARA sales. It also notes that worldwide sales do not reflect significant seasonality, but fourth-quarter spending is typically heavier, driven mainly by advertising and R&D decisions. That pattern can matter when modeling year-end margins.

Macro & geopolitical exposure

As a Drug Manufacturers - General company, Johnson & Johnson is exposed to the macro forces that shape global pharma and medtech. First, regulatory and reimbursement policy is central: FDA approvals, pricing rules, Medicare/Medicaid reimbursement, and foreign equivalent agencies directly affect revenue and margins. Second, patent and biosimilar dynamics are industry-defining; the data already show biosimilars pressuring STELARA, and the concentration in DARZALEX/TREMFYA makes future exclusivity and competition a recurring theme. Third, currency and cross-border trade matter because products are sold “in virtually all countries of the world” — a stronger dollar can compress translated international revenue and vice versa, while tariffs or trade restrictions can alter device supply chains and component costs.

Fourth, product liability and litigation risk is an inherent feature of pharma and consumer health, even though the data do not cite a specific current case. Fifth, commodity and supply-chain inputs can affect MedTech margins, particularly for metals, plastics, and electronic components used in orthopaedics, surgery, and cardiovascular devices. The combination of regulatory, pricing, and competitive forces means the sector is less cyclical than industrials but still highly sensitive to policy and legal developments.

Recent developments

The most recently dated news cluster, all from October 5, 2026, gives a quick read of how the stock is being discussed:

• defenseworld.net: “Johnson & Johnson $JNJ Shares Sold by Argent Capital Management LLC.” This is a routine institutional-flow headline, not a commentary on fundamentals, but it does indicate a reduction by one money manager.
• zacks.com: “Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation.” The framing directly ties JNJ to patent-exposure and relative-valuation conversations.
• fool.com: “2 Beaten-Down Stocks Worth Buying and Holding for the Next Decade.” JNJ appeared in this longer-horizon, defensive-growth discussion.
• fool.com: “Looking for a Dividend Stock That Can Weather a Downturn? Start With Johnson & Johnson.” This piece emphasized the company’s typical role as a downturn-resistant dividend name.

Taken together, the October 5 headlines mix institutional selling disclosure with bullish long-term commentary, reflecting the split narrative around a mature, large-cap pharma name: steady cash generation versus near-term price and valuation concerns.

Earnings behavior & post-earnings drift

Johnson & Johnson has delivered strong earnings consistency. Over the last eight reported quarters, the company beat the official estimate in seven of eight, with an average earnings surprise of 3.4%. The average five-day price move in the trading sessions following those reports has been +0.67%, classified as an “up” drift.

The four most recent quarters illustrate both the reliability and the volatility packed into that average:

• July 15, 2026: EPS of $2.90 versus estimate $2.84, a 2.1% surprise. The stock rose 1.19% the next day and 3.49% over the following five days.
• April 14, 2026: EPS of $2.70 versus estimate $2.68, a 0.7% surprise. Despite the beat, the stock fell 0.6% the next day and 5.81% over five days.
• January 21, 2026: EPS of $2.46 matched the $2.46 estimate exactly (inline). The stock ticked up 0.22% the next day and gained 4.45% over five days.
• October 14, 2025: EPS of $2.80 versus estimate $2.76, a 1.4% surprise. The stock moved up 0.17% the next day and 0.54% over five days.

The next report is scheduled for October 13, 2026, before the market open, with a consensus EPS estimate of $2.78. The history shows that beats are common but do not guarantee positive price reaction — the April 2026 quarter is a clear example of a small beat still being followed by a sharp sell-off over the next week.

For a deeper perspective on how this profile is being interpreted across the Street, look at the full institutional verdict for a more detailed dive into consensus positioning and risk factors.